ICI LUNG CANCER COURSE
The primary target audience for this course comprise the multidisciplinary clinical cancer care team members including, but not limited to medical, surgical, and radiation oncologists; fellows; gastroenterologists; nephrologists; neurologists; pathologists; pulmonologists; radiologists; researchers; oncology nurse practitioners and oncology nurses; Oncology pharmacists; Oncology PharmTechs; Oncology clinical officers; physician assistants; and other allied health care professionals.
Statement of Need
General internists, specialist health care professionals and Primary Care Clinicians must maintain an extensive knowledge base on a wide variety of topics covering all body systems as well as common and uncommon disorders. International Cancer Institute’s Lung Cancer Course aims to leverage the expertise of its Faculty to help clinicians understand best practices in diagnosis and management of Lung Cancer as encountered in the clinical settings in Kenya and sub-Saharan Africa.
At the end of this educational activity, participants should be able to:
- To learn about lung cancer data in Kenya and sub-Saharan Africa (SSA)
- To learn about the evidence-base for lung cancer screening
- To understand diagnostic modalities including the role of Biopsies / Re-Biopsies / Liquid Biopsy in Patients with NSCLC
- To learn about the TNM staging and the different subtypes of NSCLC
- To understand the different treatment strategies in NSCLC
- To learn about the management of early stage Non-Small-Cell Lung Cancer and use of adjuvant treatments
- To understand the role of multi-modality treatment in locally advanced NSCLC and limited stage SCLC
- To learn about the management of patients with actionable driver mutations and novel targeted agents for advanced NSCLC (Personalized Therapies)
- To understand the role of immune-checkpoint blockade for lung cancer and to learn about novel immunotherapies
- To learn about the systemic treatment of mesothelioma and SCLC
- To learn about the role of supportive and palliative care for lung cancer KEHPCA
- To discuss the role and integration of Biosimilars in lung cancer management
Disclosure of Conflicts of Interest
International Cancer Institute (ICI) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by ICI for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty must report any financial relationships or contractual relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA or KPPB. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Method of Participation and Request for Credit
To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately.
The Program (Tentative Dates; October 18th -21st 2021)
|Date||8 am- 10: 30 am||11 am- 1pm||2 pm -5 pm|
|Day 1, 18th Oct 2021||Registration, Orientation to the course and Pre-test||Lung Cancer Data in Kenya and SSA||Lung Cancer Prevention, Screening and Early detection|
|Day 2, 19th Oct 2021||Lung Cancer Diagnostics & Pathology||NSCLC staging and Treatment||SCLC staging and Treatment|
|Day 3, 20th Oct 2021||Role of surgery in management of Lung Cancer||Role of Radiotherapy in management of lung cancer||Mesothelioma|
|Day 4, 21st Oct 2021||Supportive and Palliative care in Lung Cancer (KEHPCA)||Supportive and Palliative care in Lung Cancer (KEHPCA)||Biosimilars in Lung cancer Management and Post-Test|
Participants should be willing to spend all the 4 days for this course to get credit for participation
No Reviews found for this course.